Novartis’ fourth-quarter performance saw net sales decline 1% at constant currencies to $13.3 billion, a reflection of the accelerating impact of U.S. competition and revenue deduction adjustments, ...
In today’s Pharmaceutical Executive Daily, a new a is expected to evolve in 2026, the FDA rejects AstraZeneca’s application ...
The organization’s 2026 Breast Cancer Progress Outlook reflects the positive progress in early detection and awareness, showing that breast cancer mortality in the United States has declined 44% ...
SanegeneBio and Genentech entered a global licensing agreement aimed at advancing an RNA interference (RNAi) therapeutic ...
The FDA rejected AstraZeneca's subcutaneous Saphnelo application, delaying U.S. approval until 2026, despite positive ...
PE: What was your experience debuting Trialynx at JP Morgan Healthcare 2026? Schwab: It’s fantastic. This was the culmination ...
On February 1, FDA announced a new pilot program designed to promote the construction of domestic manufacturing sites, along ...
According to public statements and social media posts from X, ACIP vice chair Robert Malone (a public ally of HHS secretary Robert F. Kennedy Jr.) publicly accused FDA Commissioner Marty Makary of ...
Eli Lilly is investing $3.5 billion in a new manufacturing facility in Lehigh Valley, Pennsylvania, to produce injectable ...
Dave Carey, CEO, Preceptis Medical and Michael Manavukas, CEO, co-founder, AcuityMD note the importance of shifting ear tube procedures into the office, reducing anesthesia risk, and how AI-driven ...
The deal underscores a broader shift in autoimmune drug development toward therapies that aim to reprogram disease-driving ...
AstraZeneca entered a strategic collaboration with CSPC Pharmaceuticals to expand its weight management and metabolic disease ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results